Schaberg D R
Department of Medicine, University of Tennessee-Memphis.
Ann Emerg Med. 1994 Sep;24(3):462-4. doi: 10.1016/s0196-0644(94)70185-7.
Antimicrobial resistance in Gram-positive bacteria has reemerged in the last decade as a major clinical problem. Methicillin-resistant staphylococci, penicillin-resistant pneumococci, and enterococci resistant to penicillin, vancomycin, and/or gentamicin have become new considerations in the selection of therapy. Both mutation and acquisition of new DNA on either the chromosome or plasmids can be responsible for resistance in Gram-positive species. Because therapies are often limited, renewed efforts are needed to understand the epidemiology in order to effect control.
革兰氏阳性菌的耐药性在过去十年中再次成为一个主要的临床问题。耐甲氧西林葡萄球菌、耐青霉素肺炎球菌以及对青霉素、万古霉素和/或庆大霉素耐药的肠球菌，已成为治疗选择中的新考量因素。染色体或质粒上新DNA的突变和获得都可能导致革兰氏阳性菌产生耐药性。由于治疗方法往往有限，因此需要重新努力了解其流行病学情况以实现控制。
